Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To improve segregation between ADC and SqCC in small samples, the classification of lung cancer was updated in 2011, adding immunohistochemistry (IHC) for p63 and TTF-1 to the diagnostic algorithm.
|
25982011 |
2015 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A common set of genes dysregulated in lung cancer was obtained, including BPA1, DUSP6, ASCL1, RNAS1 and S100P. p63 and CK 5/6 p63 are useful for differentiating adenocarcinoma and small cell lung cancer from squamous cell carcinoma.
|
20332665 |
2010 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results signify the importance of P63 4A4+Y4A3 marker over the old markers and may be used as a confirmatory marker of squamous cell carcinoma.
|
22631682 |
2012 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
PTEN was down-regulated in both VC and SCC, whereas p63 was down-regulated in VC but up-regulated in SCC.
|
22690848 |
2012 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Beside a role in normal development/differentiation, high p63 immunoreactivity is also frequently observed in squamous cell carcinoma (SCC).
|
24732135 |
2014 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that Snail-induced epithelial-to-mesenchymal transition (EMT) is accompanied by down-regulation of p63 in human squamous cell carcinomas (SCC).
|
17909026 |
2007 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
D2-40 and P63 expression highlighted both PAC and SCC and seems to be useful in excluding metastatic BrCa with a sensitivity and specificity of 58% and 100%, and 98% and 100%, respectively.
|
29781860 |
2018 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Spatial proximity between bronchus and ALK-rearranged tumors and frequent solid histologic subtype with p63 expression may cause diagnostic difficulties to differentiate squamous cell carcinoma in the small biopsy, whereas p40 was rarely expressed in ALK-rearranged adenocarcinoma.
|
24194854 |
2013 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
For differential diagnosis, immunostaining markers such as CK5/6 and p63 can be used to distinguish SCC and CK7 for adenocarcinoma.
|
27889037 |
2017 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, p63 siRNA significantly suppressed p-Akt and induced Akt expression in esophageal squamous carcinoma cell lines.
|
24718831 |
2014 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The IHC marker p40 (ΔNp63) is a truncated isoform of p63 that is a promising IHC marker for SQCC.
|
24166777 |
2014 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Remarkably, a similar spectrum of phenotypic alterations is observed in human syndromes resulting from Tp63 gene mutations. p63 is an important hub in the transcriptional and signaling networks of epithelial cells; thus, it is not surprising that dysregulation of this transcription factor is associated with squamous cell carcinoma.
|
21646640 |
2012 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 5/6 (CK5/6), p63, and p40 are commonly used as immunohistochemical markers for squamous cell carcinoma (SqCC) of the lung.
|
30546464 |
2018 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The SSP was developed in 68 NSCLC tumors of adenocarcinoma (AC), squamous cell carcinoma (SqCC) and large-cell neuroendocrine carcinoma (LCNEC) histology, based on NanoString expression of 11 (CHGA, SYP, CD56, SFTPG, NAPSA, TTF-1, TP73L, KRT6A, KRT5, KRT40, KRT16) relevant genes for IHC-based NSCLC histology classification.
|
30914778 |
2019 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Routinely processed mucosal biopsy or resection specimens that contained normal esophageal squamous epithelium (n = 20), squamous dysplasia (n = 4), squamous cell carcinoma (n = 7), BE (n = 10), BE-associated multilayered epithelium (n = 13), esophageal mucosal gland ducts (n = 10), BE-associated dysplasia (n = 12), and BE-associated adenocarcinoma (n = 7) were immunostained for p63 to determine the extent and location of staining. p63 staining was compared with the staining patterns observed for p53, Ki 67 (proliferation marker), and cytokeratins (CKs) 13 (squamous marker), 14 (basal squamous marker), 8/18 (columnar marker), and 19 (basal/columnar marker).
|
11727253 |
2001 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The identification of the SCC-associated interaction between SOX2 and p63 will enable deeper characterization the downstream targets of this interaction in SCC and normal squamous epithelial physiology.
|
24590290 |
2014 |
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most frequent gain was located on 3q26-29 including the gene TP63 in SCCs and 7q11.23 and 7q36.3 in ACs.
|
26003479 |
2015 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ROCK-dependent phosphorylation of NUP62 regulates p63 nuclear transport and squamous cell carcinoma proliferation.
|
29217659 |
2018 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Recent studies showed that p63 is over-expressed in some human squamous cell carcinomas of the head and neck, suggesting a role in carcinogenesis.
|
20607803 |
2010 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry assay confirmed the positive expression of CK5/6 and p63 in pancreatic SCC.
|
28099906 |
2017 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that some SCC cell lines are deficient in global nucleotide excision repair and support a role for p63 as a regulator of nucleotide excision repair in SCCs.
|
27499003 |
2016 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Many significant genes at the 3q26.2-q29 regions previously linked to a specific histology, such as EVI1,MDS1, PIK3CA and TP73L, were observed in SCC (P < 0.05).
|
19607727 |
2009 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The p63 genomic sequence was amplified in 88% of squamous carcinomas, in 42% of large cell carcinomas, and in 11% of adenocarcinomas of the lung.
|
14612504 |
2003 |
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, analysis of samples from patients with squamous cell carcinoma (SCC), basal cell carcinoma and precursors to invasive SCC demonstrated a significant correlation between p63 and VDR levels when compared with healthy normal skin control samples.
|
26068789 |
2015 |
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma.
|
29454790 |
2018 |